Figures & data
Figure 1 Transdermal oxybutynin system for overactive bladder.
Figure 2 Reduction in urge incontinence episodes.
Figure 3 Dry mouth tolerability in subjects treated with transdermal oxybutynin versus immediate-release oxybutynin.
Figure 4 Skin reactivity of transdermal oxybutynin: erythema.
Figure 5 Skin reactivity of transdermal oxybutynin: pruritus.
Figure 6 Oxybutynin and DEO levels based on route of administration. Copyright © 2005. Alberti I, Grenier A, Kraus H, et al. 2005. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv, 2:935–50.
Abbreviations: ATD™, Advanced Transdermal Delivery; DEO, N-desethyloxybutynin.
